MedicaidJuly 7, 2023
Clinical Criteria updates - December 2022
On May 20, 2022, August 19, 2022, September 12, 2022, November 18, 2022, December 12, 2022, and January 12, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem Blue Cross and Blue Shield Medicaid (Anthem). These policies were developed, revised, or reviewed to support clinical coding edits.
Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email.
Please see the explanation/definition for each category of Clinical Criteria below:
- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive.
Please share this notice with other providers in your practice and office staff.
Please note:
- The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Document number | Clinical Criteria title | New or revised |
August 12, 2023 | *CC-0226 | Elahere (mirvetuximab) | New |
August 12, 2023 | *CC-0227 | Briumvi (ublituximab) | New |
August 12, 2023 | *CC-0228 | Leqembi (lecanemab) | New |
August 12, 2023 | *CC-0229 | Sunlenca (lenacapavir) | New |
August 12, 2023 | CC-0029 | Dupixent (dupilumab) | Revised |
August 12, 2023 | CC-0185 | Oxlumo (lumasiran) | Revised |
August 12, 2023 | *CC-0072 | Selective Vascular Endothelial Growth Factor (VEGF) Inhibitors | Revised |
August 12, 2023 | CC-0130 | Imfinzi (durvalumab) | Revised |
August 12, 2023 | CC-0223 | Imjudo (tremelimumab-actl) | Revised |
August 12, 2023 | CC-0145 | Libtayo (cemiplimab-rwlc) | Revised |
August 12, 2023 | CC-0092 | Adcetris (brentuximab vedotin) | Revised |
August 12, 2023 | CC-0128 | Tecentriq (atezolizumab) | Revised |
August 12, 2023 | *CC-0107 | Bevacizumab for Non-ophthalmologic Indications | Revised |
August 12, 2023 | *CC-0166 | Trastuzumab Agents | Revised |
August 12, 2023 | *CC-0182 | Iron Agents | Revised |
August 12, 2023 | *CC-0002 | Colony Stimulating Factor Agents | Revised |
August 12, 2023 | *CC-0075 | Rituximab agents for Non-Oncologic Indications | Revised |
August 12, 2023 | *CC-0001 | Erythropoiesis Stimulating Agents | Revised |
August 12, 2023 | *CC-0062 | Tumor Necrosis Factor Antagonists | Revised |
August 12, 2023 | *CC-0167 | Rituximab Agents for Oncologic Indications | Revised |
KYBCBS-CD-020010-23-CPN19724
PUBLICATIONS: August 2023 Provider Newsletter
To view this article online:
Visit https://providernews.anthem.com/kentucky/articles/clinical-criteria-updates-december-2022-8-14314
Or scan this QR code with your phone